Portada Simposios - Supplements - Haematologica

52 Haematologica (ed. esp.), volumen 85, supl. 2, octubre 2000
proto-oncogenes al ser activadoras del ciclo. Se ha encontrado
que un 50 % de los LNH presentan sobreexpresión
de fosfatasa cdc25B, incrementándose a un
80 % cuando se trata de LNH de alto grado de malignidad.
Esta sobreexpresión va unida a una expresión
también incrementada del oncogén c-myc que parece
ser regulador de la transcripción de fosfatasas cdc25A
y B 135 ; de esta manera, se unirían el potencial oncogénico
de c-myc con la activación de la progresión del
ciclo celular ejercido por las fosfatasas cdc25.
Agradecimientos
Este trabajo ha sido financiado en parte por el Proyecto
FIS/SS n.º 99/1243.
Bibliografía
1. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order
of cell cycle events. Science 1989; 246: 629-634.
2. Pardee AB. G1 events and regulation of cell proliferation. Science
1989; 246: 603-608.
3. Solomon MJ, Harper JW, Shuttleworth J. CAK, the p34cdc2 activating
kinase, contains a protein identical or closely related to
p40Mo15. EMBO J 1993; 12: 3133-3142.
4. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C et al. A family
of human Cdc2-related protein kinases EMBO J 1992; 11:
2909-2917.
5. Pines J. Protein kinases and cell cycle control. Semin Cell Biol 1994; 5:
399-408.
6. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M et al.
Human cyclin E, a new cyclin that interacts with two members of the
Cdc2 gene family. Cell 1991; 66: 1217-1228.
7. Quelle DE, Ashmun RA, Shurleff SA, Kato JY, Bar-Sagi D, Roussell MF
et al. Overexpression of mouse D-type cyclins accelerates G1 phase in
rodent fibroblasts. Genes Dev 1993; 7: 1559-1571.
8. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a
nuclear protein required for cell cycle progression in G1. Genes Dev
1993; 7: 812-821.
9. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. Adhesion-dependent
cell cycle progression linked to the expression of cyclin
D1, activation of cyclin E-CDK2, and phosphorylation of the retinoblastoma
protein. J Cell Biol 1996; 133: 391-403.
10. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S et al.
Formation and activation of a cyclin E-CDK2 complex during the G1
phase of the human cell cycle. Science 1992; 257: 1689-1694.
11. Okamoto K, Beach D. Cyclin G is a transcriptional target for the p53
tumor suppressor protein. EMBO J 1994; 13: 4816-4822.
12. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is
required at two points in the human cell cycle. EMBO J 1992; 11:
961-971.
13. Minshull J, Golsteyn R, Hill CS, Hunt T. The A-and B-type cyclin associated
Cdc2 kinases in Xenopus turn on and off at different times in
the cell cycle. EMBO J 1990; 9: 2865-2875.
14. Matshusime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato J-Y.
D-type cyclin dependent kinase activity in mammalian cells. Moll Cell
Biol 1994; 14: 2066-2076.
15. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S et al.
Formation and activation of a cyclin E-CDK2 complex during the G1
phase of the human cell cycle. Science 1992; 257: 1689-1694.
16. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
17. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992; 70:
523-526.
18. Lane DP. P53 and human cancers. Br Med Bull 1994; 50: 582-599.
19. Wu X, Bayle JH, Olson D, Levine AJ. The p53-MDM2 autoregulatory
feedback loop. Genes Dev 1993; 7: 1126-1132.
20. Surmacz E, Reiss K, Sell C, Baserga R. Cyclin D1 messenger RNA is inducible
by platelet-derived growth factor in cultured fibroblasts. Cancer
Res 1992; 52: 4522-4525.
21. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C. Structure and
cell cycle-regulated transcription of the human cyclin A gene. Proc Natl
Acad Sci USA 1994; 91: 5490-5494.
22. Ducommun B, Brambilla P, Felix MA, Franza BR, Karsenti E, Draetta
G. Cdc2 phosphorylation is required for its interaction with cyclin.
EMBO J 1991; 10: 3311-3319.
23. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity
by phosphorylation of Thr160 and tyr15. EMBO J 1992; 11:
3995-4005.
24. Lee TH, Turck C, Kirschner MW. Inhibition of Cdc2 activation by
INH/PP2A. Mol Biol Cell 1994; 5: 323-338.
25. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H et al.
Cdcd25A is a novel phosphatase functioning early in the cell cycle.
EMBO J 1994; 13: 1549-1556.
26. Nagata A, Igarashi M, Jinno S, Suto K, Okayama H. An additional
homologue of the fission yeast Cdc25 gene occurs in humans and is
highly expressed in some cancer cells. New Biol 1991; 3: 959-968.
27. Ogg S, Gabrielli B, Piwnica-Worms H. Purification of a serine kinase
that associates with and phosphorylates human Cdc25C on serine
216. J Biol Chem 1994; 269: 30461-30469.
28. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a
target of c-myc. Nature 1996; 382: 511-517.
29. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et
al. Waf1, a potential mediator of p53 tumor suppression. Cell 1993;
75: 817-825.
30. Poliak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst
P et al. Cloning of p27KIP, a cyclin-dependent kinase inhibitor and a
potential mediator of extracellular antimitogenic signals. Cell 1994;
78: 59-66.
31. Matsuoka S, Edwards MC, Bai C, Parkers S, Zhang P, Baldini A et al.
p57KIP2, a structurally distinct member of the p21KIP1 CDK inhibitor
family, is a candidate tumor suppressor gene. Genes Dev 1995; 9:
650-662.
32. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21
are components of cell cycle kinase complexes. Mol Biol Cell 1993; 4:
897-906.
33. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming
growth factor beta induces the cyclin-dependent kinase inhibitor p21
through a p53-independent mechanism. Proc Natl Acad Sci USA
1995; 92: 5545-5549.
34. Nakayama K, Ishida N, Shirane M, Inomata A, Inove T, Shishido N et
al. Mice lacking p27(KIP1) display increased body size, multiple organ
hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85:
707-720.
35. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle
control causing specific inhibition of cyclin D/CDK4. Nature 1993;
366: 704-707.
36. Hannon GJ, Beach D. P15INK4b is a potential efector of TGF-beta induced
cell cycle arrest. Nature 1994; 371: 257-261.
37. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins,
p19 and p18, are specific inhibitors of the cyclin D-dependent
kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-2681.
38. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker
KJ et al. Reciprocal Rb inactivation and p16INK4 expression in
primary lung cancers and cell lines. Cancer Res 1995; 55: 505-509.
39. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D et al.
Complex structure and regulation of the p16 (MTS1) locus. Cancer
Res 1995; 55: 2988-2994.
40. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ et al. A
novel p16INK4a transcript. Cancer Res 1995; 55: 2995-2997.
41. Hirama T, Koeffler HP. Role of the cyclin dependent kinase inhibitors
in the development of cancer. Blood 1995; 86: 841-854.
42. Lukas J, Parry D, Agaard L, Mann DJ, Bartkova J, Strauss M et al. Retinoblastoma
protein dependent cell cycle inhibition by the tumour suppressor
p16. Nature 1995; 375: 503-506.
43. Medema RH, Herrera RE, Lam F. Growth suppression by p16/INK4 requires
functional retinoblastoma protein. Proc Natl Acad Sci USA
1995; 92: 6289-6293.
44. Shapiro GI, Park JE, Edwards CD. Multiple mechanism of p16INK4
inactivation in non-small lung cancer cell lines. Cancer Res 1995; 55:
6200-6209.
45. Alcorta DA, Xiong Y, Phelps D. Involvement of the cyclin-dependent kinase
inhibitor p16(INK4a) in replicative senescence of normal human
fibroblasts. Proc Natl Acad Sci USA 1996; 93: 13742-13747.
46. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of
p16CDKN2 expression and its implications for cell immortalization
and senescence. Mol Cell Biol 1996; 16: 859-867.
47. Quelle DE, Zindy F, Ashman RA. Alternative reading frames of the
INK4A tumor suppressor gene encode two unrelated proteins capable
of inducing cell cycle arrest. Cell 1996; 83: 993-1000.
48. Ligget WH, Sidransky D. Role of the p16 tumor suppressor gene in
cancer. J Clin Oncol 1998; 16: 1197-1206.
49. Zhang Y, Xiong Y. Yarbrough WG. ARF promotes MDM2 degradation
and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and
p53 tumor suppression pathways. Cell 1999; 92: 725-734.
50. Robles MTS, Symonds H, Chen J. Induction versus progression of
brain tumor development: differential functions for the pRb and p53
targeting domains of simian virus 40 T antigen. Mol Cell Bio 1994; 14:
2686-2698.
51. Sanding V, Brand K, Herwig S. Adenovirally transferred p16 INK4/CDKN2
and p53 genes cooperate to induce apoptotic tumor cell death. Nature
1997; 3: 313-319.
52. Robertson KD, Jones PA. Tissue-specific alternative splicing in the human
INK4a/ARF cell cycle regulatory locus. Oncogene 1999; 18:
3810-3820.
53. Kamb A, Gruis NA, Waver Fedhaus H, Liu Q, Harshman D, Tavtigian
SV Stockert Day RS, Johnosn BE, Skolnick MH. A cell cycle regulator
potentially involved in genesis of many tumor types. Science 1994;
264: 4364-4370.
54. Stone S, Dayananth P, Jiang P, Weaver Fedhaus JM, Tavtigian SV, Cannon
Albright L et al. Genomic structure, expression and mutational
analysis of the p15(MTS2) gene. Oncogene 1995; 11: 987-991.
55. Guan KL, Jenkins CW, Li Y, Nichos MA, Wu X, O’Keefe CL et al. Growth
suppression by p18, a p16INK4a/MTS1 and p14INK4b/MTS2 related
CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev
1994; 8: 2939-2952.